This site is intended for healthcare professionals in United Arab Emirates




Sign InLog Out Our MedicinesTherapy AreasExplore ContentExplore ContentDownloadable materials
Let's ConnectLet's ConnectContact usPfizer medical information

Adverse event reporting can be found at the bottom of the page



MOA MOA MOA EfficacyEfficacyPALOMA-2 Study designPatient Characteristics Primary endpoint Secondary end point PALOMA-3Study design Patient Characteristics Primary endpoint Secondary end point SurvivalFinal analysis Subgroup analysis Prespecified groups Updated Subgroup analysis Safety Safety PALOMA pooled analysis Adverse reactions  & Laboratory abnormalities PALOMA 2 Adverse Events PALOMA 3 Adverse Events IBRANCE consistent  safety profile Pooled analysis of patients aged ≥65 years in the PALOMA trials No evidence of cumulative or delayed toxicity with up to 50 months Patients with visceral diseases GI ,  Liver toxicities, and QTC Dosing Dosing Once daily dosing Dose Modification Real-World EvidenceReal-world EvidenceIBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience Real-world data provide additional information Favorable progression free rates IRIS Study In the real world, IBRANCE benefits GuidelinesGuidelinesNCCN Guidelines ESMO Guidelines Support & Services Support & Resources Patient support program/tools Events Materials Videos
Ibrance®  US Prescribing Information  Click Here
IBRANCE in combination with fulvestrant in first-line or later treatment doubled mPFS versus placebo + fulvestrant in patients with progression on/after ET in the PALOMA-3 trial*1,2In a 2:1 randomised, double-blind, Phase III trial of women with HR+/HER2- mBC whose disease progressed following ET (N = 521)1
Adapted from Cristofanilli M, et al. 20161; Ibrance SmPC.2
*Evaluated according to RECIST Version 1.1.1
Data cut-off date: 16 March 2015.
Updated non-prespecified analysis. Data cut-off date: 23 October 2015.
CI = confidence interval; ET = endocrine therapy; FUL = fulvestrant; HER2- = human epidermal growth factor receptor 2-negative; HR+= hormone receptor-positive; HR = hazard ratio; mBC = metastatic breast cancer; mPFS = median progression-free survival; PALOMA-3: the Palbociclib ongoing trials in the management of breast cancer 3 PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumours; SmPC = summary of product characteristics.

References: 1. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439. 2. Master Gulf Levant-LPD-(Ibrance)-Capsules - 75 mg, 100 mg & 125 mg based on USPI date of Revision: December 2022 for UAE.
Improved tumour response with IBRANCE + fulvestrant versus placebo + fulvestrant in first-line or later treatment (secondary end point)1Adapted from Ibrance [Local Product Document] Revision December 2022.1
Data cut-off date: 23 October 2015.
*Defined as confirmed CR or PR.2
Defined as confirmed CR or PR or SD for ≥24 weeks.2
CBR = clinical benefit rate; CR= complete response FUL = fulvestrant; ITT = intention-to-treat; ORR = objective response rate; PR= partial response; PLA = placebo; SR= stable disease.
References: 1. Master Gulf Levant-LPD-(Ibrance)-Capsules - 75 mg, 100 mg & 125 mg based on USPI date of Revision: December 2022 for UAE. 2. Turner NC, et al. Ann Oncol. 2018;29(3):669-680.

Prescribing Information: Master GULF LEVANT-LPD- (Ibrance)- Capsules- 75 mg, 100 mg &125 mg based on USPI Revision date: December 2022 – United Arab Emirates


Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign inRegisterAccountSign Out

Copyright © 2023 Pfizer Gulf FZ LLC. All rights reserved.


i- The product information provided in this site is intended only for Healthcare Professionals of UAE. The products discussed herein may have different product labeling in different countries.


ii- The information provided on this website is intended only for healthcare professionals of UAE.